Buprenorphine

17-(Cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-6,14-ethenomorphinan-7-methanol

Subutex, Suboxone, Buprenex, Temgesic, Bupe

Psychoactive Class

Chemical Class

Buprenorphine is a semisynthetic opioid of the morphinan class, first discovered in 1966 at Reckitt & Colman's research laboratories in England.¹ It functions as a partial mu-opioid receptor agonist with high binding affinity but lower intrinsic activity than full agonists such as heroin or methadone.² Used clinically for both pain management and opioid addiction treatment,³ its slow receptor dissociation produces an unusually long duration of action.⁴ Respiratory depression from overdose is considered less likely than with other opioids.²⁵

Dosage & Duration

Dosage

Threshold~0.2 mg

Light0.2-0.4 mg

Moderate0.4-0.8 mg

Strong0.8-1.5 mg

Heavy1.5+ mg

Onset and duration are dose-dependent; low doses typically produce effects for 8-12 hours, while higher doses may extend duration to 24-72 hours.

Duration

Onset30-60 minutes

Peak1-4 hours

Total8-72 hours

Subjective Effects

The buprenorphine experience is that of a classical opioid softened at the edges: pain relief, sedation, and a warm sense of contentedness are present, but its euphoric and sedative properties are notably less pronounced than those of full agonist opioids, a consequence of its partial agonism at the mu-opioid receptor. Mood effects can swing in either direction, with both euphoria and dysphoria reported. Its ceiling effect gives it a lower risk of respiratory depression than most opioids, contributing to its reputation as comparatively safe and its widespread use in substitution treatment.

Physical

The body experience is one of relaxation, drowsiness, and blunted pain, accompanied by the standard opioid side-effect profile of itching, constipation, constricted pupils, and nausea. Sweating, insomnia, dizziness, and headache may also occur, and chronic use can suppress libido and sexual function.

Sedation

Sedative and analgesic effects define the body experience, though both are milder than with full agonist opioids.

Uncomfortable

The typical opioid side-effect cluster occurs, though generally less pronounced than with other opioids.

Itchiness Dry mouth Increased perspiration Dizziness HeadachesInsomnia

Cognitive

The headspace centers on mood alteration rather than perceptual change — an elevated, contented emotional tone in most users, though dysphoric mood and irritability can occur instead. Memory impairment and general cognitive and psychomotor dulling are reported, particularly with ongoing use.

Emotional

Mood effects are the dominant cognitive component and are less intense than those of full agonist opioids.

Irritability

Suppressions

General cognitive and psychomotor impairment is reported alongside memory difficulties.

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

Buprenorphine acts as a partial agonist at the mu-opioid receptor with high binding affinity but lower intrinsic activity relative to full agonists⁶⁷, producing a ceiling effect at higher doses where its effects plateau rather than continuing to increase⁶. It functions as an antagonist at both the kappa-opioid and delta-opioid receptors⁸. Buprenorphine also acts at the nociceptin (ORL-1) receptor, where it has been characterized as both a full agonist and a partial agonist⁴. Its slow dissociation from the mu-opioid receptor (approximately 166 minutes) contributes to its prolonged duration of action⁷.

Pharmacokinetics

Buprenorphine is primarily metabolized in the liver via CYP3A4 and CYP3A5-mediated N-dealkylation to norbuprenorphine⁹¹⁰. Both buprenorphine and norbuprenorphine undergo further glucuronidation to inactive metabolites (buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide)⁶. Bioavailability is very high following intravenous administration, lower by the sublingual or buccal route, and very low when taken orally⁴¹⁰. The elimination half-life of sublingual buprenorphine has been measured at approximately 31 hours⁶.

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AlcoholBenzodiazepinesCocaineDXMGHB/GBLKetamineMXEPregabalinTramadol

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

Diphenhydramine

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

AmphetaminesMAOIsMephedroneNitrous oxidePCP

TripSit

Tolerance

Full Tolerance

Tolerance to many effects develops with prolonged and repeated use, though the rate varies for different effects. Notably, tolerance to constipation-inducing effects develops particularly slowly. Some evidence suggests that buprenorphine tolerance may not develop as readily with chronic use compared to full opioid agonists, possibly due to its lack of delta-opioid agonism.

Baseline Reset

1-2 weeks

Half Tolerance

3-7 days

Cross Tolerance

All other opioids

Harm Potential

Addiction & Dependence

Psychological

Moderate

Long-term buprenorphine use is moderately addictive, carries a high risk of abuse, and can cause psychological dependence in some users.¹¹ Once addiction has developed, stopping suddenly may lead to cravings.

Physical

Moderate

With continued use, buprenorphine can cause opioid-type physical dependence, so stopping suddenly or tapering too quickly may produce withdrawal signs and symptoms.⁶ The withdrawal syndrome is typically milder than seen with full agonists and may be delayed in onset.⁶ Symptoms include body aches, diarrhea, nausea, anxiety, tremors, tachycardia, insomnia, sweating, and weakness.¹²

Toxicity

Hepatic

Hepatotoxicity ranging from transient asymptomatic elevations in liver enzymes to rare cases of hepatic failure, hepatic necrosis, and hepatic encephalopathy has been observed;¹³ many cases involved pre-existing liver disease, viral hepatitis co-infection, concurrent hepatotoxic drugs, or ongoing injection drug use.¹⁴

Endocrine

Ongoing opioid use can affect hypothalamic-pituitary-gonadal signaling and result in androgen deficiency, which may appear as reduced libido, impotence, erectile dysfunction, amenorrhea, or infertility;¹¹ adrenal insufficiency has also been reported, more often after use lasting longer than one month.¹¹

Respiratory

Central sleep apnea has been reported as a side effect of long-term buprenorphine use, though it may resolve with dose reduction.¹¹

Cardiovascular

QT prolongation and orthostatic hypotension may occur with buprenorphine use.¹²¹³

Seizure Risk

Among those with a history of seizures, a risk exists of further seizures.¹² No notable seizure risk is documented in individuals without pre-existing seizure disorders.

History & Culture

Discovery and Early Development

Buprenorphine emerged from a decade-long research program at Reckitt & Colman (now Reckitt Benckiser) in Hull, England, where scientists sought to synthesize opioid compounds that retained therapeutic analgesic properties while minimizing the problematic effects of physical dependence and abuse…

Legality

International

1961 Single Convention: buprenorphine is not scheduled.

1971 Convention on Psychotropic Substances: Schedule III.

1988 Convention: buprenorphine is not listed in precursor Tables I or II.

By Country

United StatesPrescription onlySchedule III narcotic

21 CFR § 1308.13; Controlled Substances Act²⁵

Current official law controls buprenorphine while permitting regulated prescription medical use in United States.

CanadaPrescription onlySchedule I · Prescription controlled

Controlled Drugs and Substances Act, Schedule I; Health Canada Drug Product Database²¹

Current official law controls buprenorphine while permitting regulated prescription medical use in Canada.

FinlandPrescription controlledCitation needed

Available by prescription as Temgesic for pain management, which can be obtained from pharmacies. Subutex for opioid addiction treatment must be dispensed through approved addiction treatment physicians rather than regular pharmacies.

GermanyPrescription onlyAnlage III controlled prescription

Betäubungsmittelgesetz, Anlage III²³

Current official law controls buprenorphine while permitting regulated prescription medical use in Germany.

NorwayClass ACitation needed

Classified as a Class A controlled substance under Norwegian drug legislation. Available as Temgesic (0.3 mg) for pain relief and Subutex and Suboxone (8 mg formulations) for opioid addiction treatment.

SwedenSchedule IV narcoticCitation needed

Classified as a Class IV controlled substance. Available as Temgesic (0.2 and 0.4 mg sublingual tablets, 0.3 mg/ml injection) and Subutex (0.4, 2, and 8 mg sublingual tablets). While any physician may technically prescribe Subutex, official guidance recommends that only practitioners at drug treatment centers prescribe it for addiction.

TurkeyRestricted prescriptionCitation needed

Available only as part of official addiction treatment programs. Requires a prescription from a physician working at an addiction clinic, must be purchased from a major hospital, and the patient must demonstrate absence of other opioid use via urine screening. Available as buprenorphine/naloxone combination preparations in 2 mg/0.5 mg and 8 mg/2 mg formulations.

AustriaPrescription medicine / SMG controlledCitation needed

Legal for medical use under the Arzneimittelgesetz (AMG). Possession or sale without a valid prescription is prohibited under the Suchtmittelgesetz (SMG). Available as Temgesic for pain and Subutex for opioid addiction treatment.

CroatiaPrescription onlyCitation needed

Available by prescription only as Subutex in 2 mg tablet form for opioid addiction treatment. While pharmacies stock the medication, prescriptions may only be written by approved addiction treatment physicians.

FrancePrescription medicineCitation needed

Prescription by general practitioners and dispensation by pharmacies has been permitted since the mid-1990s as part of harm reduction efforts addressing HIV transmission and overdose risk among people who use drugs.²²

NetherlandsList II (Opiumwet)Citation needed

Controlled under List II of the Opium Law with special rules governing prescription and dispensation. Available by prescription as Temgesic in 0.2 mg sublingual tablets for severe pain, and by injection in hospital settings.

RussiaSchedule IICitation needed

Controlled as a Schedule II substance under Russian narcotics legislation. Subject to strict prescription and distribution controls.

SwitzerlandVerzeichnis ACitation needed

Listed as a controlled substance under Verzeichnis A of the Swiss narcotics regulations. Medicinal use is permitted under appropriate medical supervision.

United KingdomPrescription onlyClass C · Schedule 3

Misuse of Drugs Act 1971; Misuse of Drugs Regulations 2001²⁴

Current official law controls buprenorphine while permitting regulated prescription medical use in United Kingdom.

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Buprenorphine article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Buprenorphine

17-(Cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-6,14-ethenomorphinan-7-methanol

Subutex, Suboxone, Buprenex, Temgesic, Bupe

Psychoactive Class

Opioid Depressant

Chemical Class

Morphinan (substituted)